Institute of Genetic Diagnosis, Department of Pharmacogenomics, School of Pharmacy, The Fourth Military Medical University, 169 Changle West Road, Xi'an 710032, Shaanxi, China.
Vaccine. 2010 Mar 16;28(13):2497-504. doi: 10.1016/j.vaccine.2010.01.038. Epub 2010 Jan 29.
Antigen-presenting autologous dendritic cells (ADCs), primed with antigen, have been used in immunotherapy. We evaluated ADCs for treatment of chronic hepatitis B (CHB). ADCs were administered to 380 CHB patients. Virological, biochemical, and serological responses were evaluated in each patient over the course of 48 weeks. Undetectable levels of HBV DNA were reported in 46.36% of patients negative for the hepatitis B "e" antigen (HBeAg) and 3.13% HBeAg-positive patients. Normalization of alanine aminotransferase levels occurred in both HBeAg-positive (P=0.007) and HBeAg-negative (P=0.003) patients. It appears that ADC vaccination effectively reconstructed the immunity and elicited virological, serological, and biochemical improvements in some patients with chronic HBV. No side effects were observed.
抗原呈递自体树突状细胞 (ADCs)，经抗原致敏后，已被用于免疫治疗。我们评估了 ADC 用于治疗慢性乙型肝炎 (CHB) 的效果。给 380 名 CHB 患者给予 ADC。在 48 周的过程中，对每位患者的病毒学、生化学和血清学反应进行了评估。在 HBeAg 阴性患者中，有 46.36%的患者报告 HBV DNA 检测不到水平，而在 HBeAg 阳性患者中，有 3.13%的患者报告 HBV DNA 检测不到水平。在 HBeAg 阳性（P=0.007）和 HBeAg 阴性（P=0.003）患者中均出现丙氨酸氨基转移酶水平正常化。似乎 ADC 疫苗接种有效地重建了免疫，并在一些慢性 HBV 患者中引起了病毒学、血清学和生化学的改善。未观察到副作用。
